Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes

January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3
Academic Journal
The article presents a clinical study that evaluates the efficacy of incretin for glycemic control in adults with non-insulin-dependent diabetes. A randomized-controlled trial showed changes in patients' glycated hemoglobin levels, weight and hypoglycemia. It is concluded that the incretin therapy is more effective than placebo in controlling glycemic level, glucagon-like peptide (GLP-1) are associated with weight loss and dipeptidyl peptidase (DDP4) inhibitors are linked with weight gain.


Related Articles

  • Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1. Riddle, Matthew C.; Drucker, Daniel J. // Diabetes Care;Feb2006, Vol. 29 Issue 2, p435 

    Discusses a study which summarized several limitations in the treatment of type 2 diabetes and describes the mechanisms of action and clinical data obtained with amylin and glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Barriers to...

  • COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes. Vella, Adrian // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are...

  • Glucagon-like peptide agonists. Gadsby, Roger // Practice Nurse;4/9/2010, Vol. 39 Issue 7, p30 

    The article discusses glucagon-like peptide 1 (GLP-1) and its potential role in the treatment of type 2 diabetes. The levels of GLP-1 in people with diabetes are reduced in response to a meal and it is easily broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). Clinical tests reveal that...

  • A gut-heart connection in cardiometabolic regulation. Buglioni, Alessia; Burnett, John C // Nature Medicine;May2013, Vol. 19 Issue 5, p534 

    The article offers information on the study of Kim and colleagues which examines the link between glucagon-like peptide-1 (GLP-1) release from the cardiac hormone atrial natriuretic peptide and gut. It states that glycemia in patients with type 2 diabetes were controlled using GLP-1 receptor...

  • Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. Dave, Darshan J. // Journal of Pharmacology & Pharmacotherapeutics;Oct2011, Vol. 2 Issue 4, p230 

    Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin defi ciency or resistance. Management starts with single oral antidiabetic drug (OAD) but eventually switch over to combination therapy because of progressive ?-cell dysfunction. Hypoglycemia, weight gain, and...

  • A Single Dose of Vildagliptin (VILDA) Decelerates Gastric Emptying. (GE) in Patients with Type 2 Diabetes (T2DM). Woerle, Hans J.; Lindenberger, Thilo; Linke, Rainer; Foley, James E.; Ligueros-Saylan, Monica A.; Zhang, Yiming; He, Yan-Ling; Beglinger, Christoph; Goeke, Burkhard; Schirra, Joerg // Diabetes;Jun2007 Supplement 1, Vol. 56, pA133 

    The dipeptidyl peptidase IV (DPP-4) inhibitor, VILDA increases postprandial (pp) GLP-1 levels 2-4 fold; this is associated with improved islet function and lower glucose (GLU) excursions. Unlike GLP-1 analogs, a multiple dose study with VILDA utilizing 50 mg bid, did not shown the known GLP-I...

  • Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes. Vaidya, H. B.; Goyal, R. K. // Current Drug Targets;Oct2008, Vol. 9 Issue 10, p911 

    Diabetes mellitus (DM) has been recognized as a growing world-wide epidemic by many health advocacy groups including the World Health Organization (WHO). DM affects about 6% of the North American population. A recent report estimated that 8.2% of adult population worldwide has impaired glucose...

  • Long-Acting Glucagon-Like Peptide 1 Receptor Agonists. GARBER, ALAN J. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS279 

    The article examines the efficacy and tolerability of long-acting glucagon-like peptide 1 receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. A definition of incretin effect is...

  • GLP-1 receptor agonist-induced polyarthritis: a case report. Ambrosio, Maria; Monami, Matteo; Sati, Lavinia; Marchionni, Niccolò; Bari, Mauro; Mannucci, Edoardo // Acta Diabetologica;Aug2014, Vol. 51 Issue 4, p673 

    Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, ). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics